assessing-leukocyte-endothelial-interactions-under-flow-conditions-an

Assessing Leukocyte-endothelial Interactions Under Flow Conditions in an <em>Ex Vivo</em> Autoperfused Microflow Chamber Assay

Leukocyte-endothelial interactions are early and critical events in acute and chronic inflammation and can, when dysregulated, mediate tissue injury ...

Harvard Medical School, Massachusetts Eye & Ear Infirmary

St. Elizabeth's Medical Center

Regulatory T cells in blood of patients with birdshot retinochoroidopathy.

Ocular neovascularization, including age-related macular degeneration (AMD), is a primary cause of blindness in individuals of industrialized countries. With a projected increase in the prevalence of these blinding neovascular diseases, there is an urgent need for new pharmacological interventions for their treatment or prevention. Increasing evidence has implicated eicosanoid-like metabolites of long-chain polyunsaturated fatty acids (LCPUFAs) in the regulation of neovascular disease. In particular, metabolites generated by the cytochrome P450 (CYP)-epoxygenase pathway have been shown to be potent modulators of angiogenesis, making this pathway a reasonable previously unidentified target for intervention in neovascular ocular disease. Here we show that dietary supplementation with ω-3 LCPUFAs promotes regression of choroidal neovessels in a well-characterized mouse model of neovascular AMD. Leukocyte recruitment and adhesion molecule expression in choroidal neovascular lesions were down-regulated in mice fed ω-3 LCPUFAs. The serum of these mice showed increased levels of anti-inflammatory eicosanoids derived from eicosapentaenoic acid and docosahexaenoic acid. 17,18-epoxyeicosatetraenoic acid and 19,20-epoxydocosapentaenoic acid, the major CYP-generated metabolites of these primary ω-3 LCPUFAs, were identified as key lipid mediators of disease resolution. We conclude that CYP-derived bioactive lipid metabolites from ω-3 LCPUFAs are potent inhibitors of intraocular neovascular disease and show promising therapeutic potential for resolution of neovascular AMD.

Lama Mulki

Angiogenesis Laboratory,
Department of Ophthalmology,
Angiogenesis Laboratory, Department of Ophthalmology

Harvard Medical School, Massachusetts Eye & Ear Infirmary

Assessing Leukocyte-endothelial Interactions Under Flow Conditions in an Ex Vivo Autoperfused Microflow Chamber Assay

Lama Mulki

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Angiogenesis Laboratory,Department of Ophthalmology,Angiogenesis Laboratory, Department of Ophthalmology

Harvard Medical School, Massachusetts Eye & Ear Infirmary

Assessing Leukocyte-endothelial Interactions Under Flow Conditions in an Ex Vivo Autoperfused Microflow Chamber Assay

Angiogenesis Laboratory,
Department of Ophthalmology,
Angiogenesis Laboratory, Department of Ophthalmology